Biosimilars and retention rates in patients with ankylosing spondylitis

Clin Exp Rheumatol. 2021 Mar-Apr;39(2):440. doi: 10.55563/clinexprheumatol/4cualr. Epub 2020 Oct 18.

Authors

Eleftherios Pelechas¹, Evripidis Kaltsonoudis¹, Paraskevi V Voulgari¹, Alexandros A Drosos²

Affiliations

¹ Division of Rheumatology, University of Ioannina Medical School, Greece.
² Division of Rheumatology, University of Ioannina Medical School, Greece. adrosos@cc.uoi.gr.

PMID: 33124580
DOI: 10.55563/clinexprheumatol/4cualr

No abstract available

Publication types

Letter

MeSH terms

Antirheumatic Agents* / adverse effects
Biosimilar Pharmaceuticals* / adverse effects
Humans
Spondylitis, Ankylosing* / diagnosis
Spondylitis, Ankylosing* / drug therapy

Substances

Antirheumatic Agents
Biosimilar Pharmaceuticals